Loading
IL7R (Interleukin-7 receptor subunit alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.
Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP).
CIViC holds 3 clinical evidence items and 0 assertions across 3 variants. Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.98, animal model 0.42, genetic association 0.36, somatic mutation 0.86). IntOGen calls it a driver in 4 cohorts (3 activating, 1 loss-of-function), covering Acute Lymphoblastic Leukaemia, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, Stomach Adenocarcinoma.
In plain words · IL7R (Interleukin-7 receptor subunit alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.
IL7R (Interleukin-7 receptor subunit alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.
Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP).
No product in this corpus aims at IL7R yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA IL7R: RNA tissue enhanced (lymphoid tissue 171 nTPM); blood lineage group enriched (NK-cells 113 nTPM, T-cells 370 nTPM); high antibody staining in 1 normal tissue. Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Leukaemia, Lymphoma, Oesophageal cancer, Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer, Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P16871; CIViC gene IL7R; IntOGen IL7R; Human Protein Atlas IL7R tissue; Open Targets ENSG00000168685 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Goodwin R.G. et al, Cell, 1990, "Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily". Source.
Sources: HGNC HGNC:6024 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P16871 (protein name, function text, keywords and locations (REST API)); CIViC gene IL7R (3 evidence items, 0 assertions, 3 variants; diseases: T-cell Acute Lymphoblastic Leukaemia, Childhood B-cell Acute Lymphoblastic Leukaemia, B-lymphoblastic Leukaemia/lymphoma, BCR-ABL1-like (GraphQL API, CC0)); Open Targets ENSG00000168685 (association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: melanoma 0.57, acute lymphoblastic leukaemia 0.59, non-Hodgkin lymphoma 0.61, skin cancer 0.64, lung cancer 0.56, leukaemia 0.62 (GraphQL API, CC0)); IntOGen IL7R (driver in 4 cohorts (Act 3, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP). Location: Cell membrane; Secreted (UniProt). Locus 5p13.2 (HGNC).
RNA: tissue enhanced (lymphoid tissue 171 nTPM), detected in many normal tissues. Blood: group enriched (NK-cells 113 nTPM, T-cells 370 nTPM).
Medium: Bone marrow, Lymph node, Spleen, Tonsil.
No cancer sample stained medium or high.
HPA IL7R tissue · HPA IL7R pathology · HPA protein class: CD markers
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"IL7R" OR ABSTRACT:"IL7R" OR TITLE:"interleukin 7 receptor" OR ABSTRACT:"interleukin 7 receptor" OR TITLE:"Interleukin-7 receptor subunit alpha" OR ABSTRACT:"Interleukin-7 receptor subunit alpha" OR TITLE:"CD127" OR ABSTRACT:"CD127" OR TITLE:"IL7RA" OR ABSTRACT:"IL7RA" OR TITLE:"lnc-IL7R" OR ABSTRACT:"lnc-IL7R") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IL7R, not a curated reading list.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, Hepatocellular carcinoma.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, Hepatocellular carcinoma.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
Shares Leukaemia (all types), Skin cancer (all types), Hepatocellular carcinoma, IntOGen.
Shares Leukaemia (all types), Skin cancer (all types), CIViC, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, IntOGen.
Shares Leukaemia (all types), Skin cancer (all types), CIViC, IntOGen.